B. Riley Has Bearish Estimate for InfuSystem FY2025 Earnings

InfuSystem Holdings, Inc. (NYSE:INFU) – B. Riley decreased their FY2025 earnings per share (EPS) estimates for shares of InfuSystem in a research note issued to investors on Tuesday, November 4th. B. Riley analyst A. Schock now forecasts that the company will earn $0.29 per share for the year, down from their prior forecast of $0.30. The consensus estimate for InfuSystem’s current full-year earnings is $0.15 per share. B. Riley also issued estimates for InfuSystem’s Q4 2025 earnings at $0.07 EPS.

INFU has been the subject of several other research reports. Roth Capital reiterated a “buy” rating and issued a $14.00 price target (up previously from $13.00) on shares of InfuSystem in a research report on Tuesday. Zacks Research lowered shares of InfuSystem from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Finally, Lake Street Capital began coverage on shares of InfuSystem in a research note on Monday, September 22nd. They set a “buy” rating and a $15.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $14.50.

InfuSystem Price Performance

INFU stock opened at $10.29 on Friday. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $210.18 million, a P/E ratio of 171.53 and a beta of 1.80. The business has a 50 day simple moving average of $10.07 and a 200-day simple moving average of $7.67. InfuSystem has a twelve month low of $4.61 and a twelve month high of $11.04.

Institutional Trading of InfuSystem

A number of institutional investors have recently added to or reduced their stakes in the stock. Minerva Advisors LLC raised its holdings in InfuSystem by 9.2% during the second quarter. Minerva Advisors LLC now owns 994,781 shares of the company’s stock worth $6,178,000 after purchasing an additional 84,104 shares during the last quarter. Russell Investments Group Ltd. grew its stake in InfuSystem by 13.1% in the 1st quarter. Russell Investments Group Ltd. now owns 437,891 shares of the company’s stock valued at $2,356,000 after acquiring an additional 50,877 shares during the last quarter. Essex Investment Management Co. LLC grew its stake in InfuSystem by 8.9% in the 3rd quarter. Essex Investment Management Co. LLC now owns 300,397 shares of the company’s stock valued at $3,112,000 after acquiring an additional 24,634 shares during the last quarter. Truffle Hound Capital LLC increased its holdings in InfuSystem by 27.8% during the 3rd quarter. Truffle Hound Capital LLC now owns 230,000 shares of the company’s stock valued at $2,383,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Cove Street Capital LLC raised its position in InfuSystem by 8.7% during the first quarter. Cove Street Capital LLC now owns 210,301 shares of the company’s stock worth $1,131,000 after acquiring an additional 16,851 shares during the last quarter. Hedge funds and other institutional investors own 71.13% of the company’s stock.

Insider Activity at InfuSystem

In other news, Director Scott Shuda sold 5,752 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $9.67, for a total transaction of $55,621.84. Following the transaction, the director directly owned 94,000 shares of the company’s stock, valued at $908,980. This represents a 5.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 11.40% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.